Virtual Library
Start Your Search
Yosuke Matsuura
Author of
-
+
P1.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 948)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.16-43 - Analyses of Long-Term Outcomes and Prognostic Factors in Surgically Resected ALK-Rearranged Lung Adenocarcinoma (ID 12721)
16:45 - 18:00 | Presenting Author(s): Yosuke Matsuura
- Abstract
Background
Anaplastic lymphoma kinase (ALK)-rearrangement (ALK+) in lung cancer has made an epoch in the molecular classification. Specific inhibitors of the kinase activity of ALK have been developed as therapeutic drugs for lung cancer with ALK+. Long-term outcomes and prognostic factors, however, in surgically resected cases are unclear. We evaluated the survival rate, and investigated association between prognosis of surgically resected lung adenocarcinoma (AC) with ALK+ and clinicopathological features.
a9ded1e5ce5d75814730bb4caaf49419 Method
From 1996 to 2013, clinical data of 62 AC patients with ALK+ were retrospectively analyzed. The median follow up time was 73 months. Relationships between the patients’ clinicopathological features (i.e. age, gender, smoking history, operative procedure, administration of adjuvant therapy, tumor size, c-stage, p-stage, pleural invasion, Ly/V invasion, intrapulmonary metastasis, histologic predominant subtypes, and histologic grade), and their recurrence-free survival (RFS), post-recurrence survival (PRS) and overall survival (OS) rates were assessed.
4c3880bb027f159e801041b1021e88e8 Result
The 5-year RFS and OS were 69% and 92%, respectively. For OS, advanced p-stage (IIIA and IV) and pleural invasion were independent poor prognostic factors in multivariate analyses, but 5-year OS for even Stage IIIA was 85%, nevertheless (Figure).
20 patients had recurrence. 8 of the 20 patients were treated with ALK-tyrosine kinase inhibitors (TKIs), and 12 were without. The median PRS was 54 months. Patients treated with AKL-TKIs had longer PRS and OS than without (65 vs. 38 months, p=0.01, and 80 vs. 74 months, p=0.04, respectively).
8eea62084ca7e541d918e823422bd82e Conclusion
Long-term outcomes in surgically resected ALK+ AC were excellent even so advanced stage. ALK-TKIs are certainly effective for post-recurrence status. For the resectable ALK+ AC treatment strategy, ALK-TKIs might play an important role.
6f8b794f3246b0c1e1780bb4d4d5dc53